HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Validation of a Muscle-Specific Tissue Image Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies.

AbstractCONTEXT.—:
Duchenne muscular dystrophy is a rare, progressive, and fatal neuromuscular disease caused by dystrophin protein loss. Common investigational treatment approaches aim at increasing dystrophin expression in diseased muscle. Some clinical trials include assessments of novel dystrophin production as a surrogate biomarker of efficacy, which may predict a clinical benefit from treatment.
OBJECTIVES.—:
To establish an immunofluorescent scanning and digital image analysis workflow that provides an objective approach for staining intensity assessment of the immunofluorescence dystrophin labeling and determination of the percentage of biomarker-positive fibers in muscle cryosections.
DESIGN.—:
Optimal and repeatable digital image capture was achieved by a rigorously qualified fluorescent scanning process. After scanning qualification, the MuscleMap (Flagship Biosciences, Westminster, Colorado) algorithm was validated by comparing high-power microscopic field total and dystrophin-positive fiber counts obtained by trained pathologists to data derived by MuscleMap. Next, the algorithm was tested on whole-slide images of immunofluorescent-labeled muscle sections from Duchenne muscular dystrophy, Becker muscular dystrophy, and control patients.
RESULTS.—:
When used under the guidance of a trained pathologist, the digital image analysis tool met predefined validation criteria and demonstrated functional and statistical equivalence with manual assessment. This work is the first, to our knowledge, to qualify and validate immunofluorescent scanning and digital tissue image-analysis workflow, respectively, with the rigor required to support the clinical trial environments.
CONCLUSIONS.—:
MuscleMap enables analysis of all fibers within an entire muscle biopsy section and provides data on a fiber-by-fiber basis. This will allow future clinical trials to objectively investigate myofibers' dystrophin expression at a greater level of consistency and detail.
AuthorsFamke Aeffner, Crystal Faelan, Steven A Moore, Alexander Moody, Joshua C Black, Jay S Charleston, Diane E Frank, Johannes Dworzak, J Kris Piper, Manish Ranjitkar, Kristin Wilson, Suzanne Kanaly, Daniel G Rudmann, Holger Lange, G David Young, Anthony J Milici
JournalArchives of pathology & laboratory medicine (Arch Pathol Lab Med) Vol. 143 Issue 2 Pg. 197-205 (02 2019) ISSN: 1543-2165 [Electronic] United States
PMID30168727 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Validation Study)
Chemical References
  • Dystrophin
Topics
  • Adolescent
  • Biopsy
  • Child
  • Child, Preschool
  • Dystrophin (analysis)
  • Female
  • Frozen Sections
  • Humans
  • Image Interpretation, Computer-Assisted (methods)
  • Male
  • Middle Aged
  • Muscle, Skeletal (pathology)
  • Muscular Dystrophy, Duchenne (diagnosis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: